Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at Annual Meeting 2018.
The benefits of using ramucirumab plus docetaxel in 2nd line NSCLC
Advertisement
By Editor
Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at Annual Meeting 2018.